Global Neurotrophic Keratitis Market Size study, by Treatment Type (Preservative Free Artificial Tears, Topical Antibiotics, Amniotic Membrane Transplantation, Tarsorrhaphy, Recombinant Human Nerve Growth Factor (rhNGF), Others) and Regional Forecasts 2020-2026

  • Product Code:
    RP-ID-10321972
  • Published Date:
    May 2020 (Upgradation in process)
  • Region:
    Global
  • Pages:
    200
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-14

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

Global Neurotrophic Keratitis Market is valued approximately USD 92 million in 2019 and is anticipated to grow with a healthy growth rate of more than 17% over the forecast period 2019-2026. Neurotrophic Keratitis (NK) is a neurodegenerative disease caused by the injury of trigeminal nerve that affects the cornea of an eye. In this disease, the patient drops the corneal sensitivity and thus cornea is unprotected to damages without treatment. If this disease is not treated and diagnosed properly, the patient can loss permanent eye vision. The treatment of neurotrophic keratitis is done by a team that includes neurologists, ophthalmologists and corneal specialists. Treatments are available based on the severity of the disease. Neurotrophic Keratitis treatment comprises topical antibiotics, bandage contact lenses, preservative artificial tears, amniotic membrane transplantation, keratoplasty, Recombinant human nerve growth factor (rhNGF), and so on. Growing number of approvals for new product innovation from regulatory authorities, with the huge financial support to the researchers for developing novel treatments are the few factors responsible for high CAGR of the market over the forecast period. For instance, in August 2018, Dompe farmaceutici S.p.A. has received approval for cenegermin topical eyes drop from FDA, which is a recombinant human nerve growth factor for the therapy of neurotrophic keratitis. The cenegermin has also obtained an Orphan Drug designation, Breakthrough Therapy designation and Fast Track status from the FDA. This, in turn, is expected to accelerate the growth of Neurotrophic Keratitis market around the world. However, low healthcare budget in some of the developing countries is one of the major factors expected to hamper the growth of the market over the forecast period of 2020-2026.

The regional analysis of global Neurotrophic Keratitis market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising product approvals, presence of well-established healthcare infrastructure, and increase in R&D activities in neurotrophic keratitis in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026, due to growing geriatric population and increasing government investments in healthcare and R&D present in the countries like China and India.

Major market player included in this report are:
Allergan, Plc.
Abbott Laboratories, Inc.
Bausch & Lomb Incorporated
Bayer AG
CooperVision
Dompe farmaceutici S.p.A.
Johnson & Johnson
Novartis AG
ReGenTree, LLC.
Walgreens

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment Type:
Preservative Free Artificial Tears
Topical Antibiotics
Amniotic Membrane Transplantation
Tarsorrhaphy
Recombinant Human Nerve Growth Factor (rhNGF)
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017, 2018
Base year – 2019
Forecast period – 2020 to 2026

Target Audience of the Global Neurotrophic Keratitis Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2026 (USD Million)
1.2.1. Neurotrophic Keratitis Market, by Region, 2018-2026 (USD Million)
1.2.2. Neurotrophic Keratitis Market, by Treatment Type, 2018-2026 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Neurotrophic Keratitis Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Neurotrophic Keratitis Market Dynamics
3.1. Neurotrophic Keratitis Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Neurotrophic Keratitis Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Neurotrophic Keratitis Market, by Treatment Type
5.1. Market Snapshot
5.2. Global Neurotrophic Keratitis Market by Treatment Type, Performance - Potential Analysis
5.3. Global Neurotrophic Keratitis Market Estimates & Forecasts by Treatment Type 2016-2026 (USD Million)
5.4. Neurotrophic Keratitis Market, Sub Segment Analysis
5.4.1. Preservative Free Artificial Tears
5.4.2. Topical Antibiotics
5.4.3. Amniotic Membrane Transplantation
5.4.4. Tarsorrhaphy
5.4.5. Recombinant Human Nerve Growth Factor (rhNGF)
5.4.6. Others
Chapter 6. Global Neurotrophic Keratitis Market, Regional Analysis
6.1. Neurotrophic Keratitis Market, Regional Market Snapshot
6.2. North America Neurotrophic Keratitis Market
6.2.1. U.S. Neurotrophic Keratitis Market
6.2.1.1. Treatment Type breakdown estimates & forecasts, 2016-2026
6.2.2. Canada Neurotrophic Keratitis Market
6.3. Europe Neurotrophic Keratitis Market Snapshot
6.3.1. U.K. Neurotrophic Keratitis Market
6.3.2. Germany Neurotrophic Keratitis Market
6.3.3. Rest of Europe Neurotrophic Keratitis Market
6.4. Asia-Pacific Neurotrophic Keratitis Market Snapshot
6.4.1. China Neurotrophic Keratitis Market
6.4.2. India Neurotrophic Keratitis Market
6.4.3. Japan Neurotrophic Keratitis Market
6.4.4. Rest of Asia Pacific Neurotrophic Keratitis Market
6.5. Latin America Neurotrophic Keratitis Market Snapshot
6.5.1. Brazil Neurotrophic Keratitis Market
6.5.2. Mexico Neurotrophic Keratitis Market
6.6. Rest of The World Neurotrophic Keratitis Market
Chapter 7. Competitive Intelligence
7.1. Top Market Strategies
7.2. Company Profiles
7.2.1. Allergan, Plc.
7.2.1.1. Key Information
7.2.1.2. Overview
7.2.1.3. Financial (Subject to Data Availability)
7.2.1.4. Product Summary
7.2.1.5. Recent Developments
7.2.2. Abbott Laboratories, Inc.
7.2.3. Bausch & Lomb Incorporated
7.2.4. Bayer AG
7.2.5. CooperVision
7.2.6. Dompe farmaceutici S.p.A.
7.2.7. Johnson & Johnson
7.2.8. Novartis AG
7.2.9. ReGenTree, LLC.
7.2.10. Walgreens
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research AssumptionList of Tables
TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL NEUROTROPHIC KERATITIS MARKET
TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL NEUROTROPHIC KERATITIS MARKET
TABLE 3. GLOBAL NEUROTROPHIC KERATITIS MARKET, REPORT SCOPE
TABLE 4. YEARS CONSIDERED FOR THE STUDY
TABLE 5. EXCHANGE RATES CONSIDERED
TABLE 6. GLOBAL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD MILLION)
TABLE 7. GLOBAL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY TREATMENT TYPE 2016-2026 (USD MILLION)
TABLE 8. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 9. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 10. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 11. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 12. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 13. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 14. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 15. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 16. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 17. GLOBAL NEUROTROPHIC KERATITIS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 18. U.S. NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 19. U.S. NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 20. U.S. NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 21. CANADA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 22. CANADA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 23. CANADA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 24. UK NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 25. UK NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 26. UK NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 27. GERMANY NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 28. GERMANY NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 29. GERMANY NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 30. ROE NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 31. ROE NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 32. ROE NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 33. CHINA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 34. CHINA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 35. CHINA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 36. INDIA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 37. INDIA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 38. INDIA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 39. JAPAN NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 40. JAPAN NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 41. JAPAN NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 42. ROAPAC NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 43. ROAPAC NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 44. ROAPAC NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 45. BRAZIL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 46. BRAZIL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 47. BRAZIL NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 48. MEXICO NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 49. MEXICO NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 50. MEXICO NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 51. ROLA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 52. ROLA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 53. ROLA NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 54. ROW NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD MILLION)
TABLE 55. ROW NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)
TABLE 56. ROW NEUROTROPHIC KERATITIS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD MILLION)List of Figures
FIG 1. GLOBAL NEUROTROPHIC KERATITIS MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL NEUROTROPHIC KERATITIS MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL NEUROTROPHIC KERATITIS MARKET, KEY TRENDS 2019
FIG 5. GLOBAL NEUROTROPHIC KERATITIS MARKET, GROWTH PROSPECTS 2020-2026
FIG 6. GLOBAL NEUROTROPHIC KERATITIS MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL NEUROTROPHIC KERATITIS MARKET, PEST ANALYSIS
FIG 8. GLOBAL NEUROTROPHIC KERATITIS MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, 2016 & 2026 (USD MILLION)
FIG 10. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, 2016 & 2026 (USD MILLION)
FIG 11. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, 2016 & 2026 (USD MILLION)
FIG 12. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, 2016 & 2026 (USD MILLION)
FIG 13. GLOBAL NEUROTROPHIC KERATITIS MARKET BY SEGMENT, 2016 & 2026 (USD MILLION)
FIG 14. GLOBAL NEUROTROPHIC KERATITIS MARKET, REGIONAL SNAPSHOT 2016 & 2026
FIG 15. NORTH AMERICA NEUROTROPHIC KERATITIS MARKET 2016 & 2026 (USD MILLION)
FIG 16. EUROPE NEUROTROPHIC KERATITIS MARKET 2016 & 2026 (USD MILLION)
FIG 17. ASIA PACIFIC NEUROTROPHIC KERATITIS MARKET 2016 & 2026 (USD MILLION)
FIG 18. LATIN AMERICA NEUROTROPHIC KERATITIS MARKET 2016 & 2026 (USD MILLION)
FIG 19. GLOBAL NEUROTROPHIC KERATITIS MARKET, COMPANY MARKET SHARE ANALYSIS (2019)
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Allergan, Plc.
Abbott Laboratories, Inc.
Bausch & Lomb Incorporated
Bayer AG
CooperVision
Dompe farmaceutici S.p.A.
Johnson & Johnson
Novartis AG
ReGenTree, LLC.
Walgreens
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports

Publisher :